415 related articles for article (PubMed ID: 15390201)
21. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma.
Lo YM; Chan LY; Lo KW; Leung SF; Zhang J; Chan AT; Lee JC; Hjelm NM; Johnson PJ; Huang DP
Cancer Res; 1999 Mar; 59(6):1188-91. PubMed ID: 10096545
[TBL] [Abstract][Full Text] [Related]
23. [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].
Peng PJ; Zhao C; Liao H; Wang FQ; Zhang L
Ai Zheng; 2002 Aug; 21(8):817-22. PubMed ID: 12478884
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.
Hassen E; Farhat K; Gabbouj S; Bouaouina N; Abdelaziz H; Chouchane L
Biomarkers; 2011 May; 16(3):274-80. PubMed ID: 21506698
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type.
Bortolin MT; Pratesi C; Dolcetti R; Bidoli E; Vaccher E; Zanussi S; Tedeschi R; De Paoli P
Cancer Lett; 2006 Feb; 233(2):247-54. PubMed ID: 15907367
[TBL] [Abstract][Full Text] [Related]
26. [Real-time quantitative PCR assay of Epstein-Barr virus in whole blood cells of nasopharyngeal carcinoma patients].
Wang H; Deng L; Chen SH; Wang SQ; Cao Y
Shi Yan Sheng Wu Xue Bao; 2003 Feb; 36(1):32-6. PubMed ID: 12751207
[TBL] [Abstract][Full Text] [Related]
27. The role of Epstein-Barr virus-encoded microRNA BART7 status of resection margins in the prediction of local recurrence after salvage nasopharyngectomy for recurrent nasopharyngeal carcinoma.
Chan JY; Wong ST; Wei WI
Cancer; 2015 Jul; 121(14):2358-66. PubMed ID: 25955785
[TBL] [Abstract][Full Text] [Related]
28. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 31 patients and prognostic factors.
To EW; Lai EC; Cheng JH; Pang PC; Williams MD; Teo PM
Laryngoscope; 2002 Oct; 112(10):1877-82. PubMed ID: 12368634
[TBL] [Abstract][Full Text] [Related]
29. [Salvage surgical operation via endoscopic transnasal approach for local persistent or recurrent nasopharyngeal carcinoma].
Chen MY; Guo X; Wen WP; Hua YJ; Guo L; Li NW; Chen QY; Sun R; Hong MH
Ai Zheng; 2007 Jul; 26(7):673-8. PubMed ID: 17626738
[TBL] [Abstract][Full Text] [Related]
30. Clinical applications of plasma Epstein-Barr virus DNA analysis and protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA.
Chan KC; Lo YM
Methods Mol Biol; 2006; 336():111-21. PubMed ID: 16916257
[TBL] [Abstract][Full Text] [Related]
31. Disparity of sensitivities in detection of radiation-naïve and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein-Barr virus DNA1,2.
Leung SF; Lo YM; Chan AT; To KF; To E; Chan LY; Zee B; Huang DP; Johnson PJ
Clin Cancer Res; 2003 Aug; 9(9):3431-4. PubMed ID: 12960133
[TBL] [Abstract][Full Text] [Related]
32. Nasopharyngectomy for recurrent nasopharyngeal carcinoma: a review of 53 patients and prognostic factors.
Hao SP; Tsang NM; Chang KP; Hsu YS; Chen CK; Fang KH
Acta Otolaryngol; 2008 Apr; 128(4):473-81. PubMed ID: 18368585
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma.
Lei KI; Chan LY; Chan WY; Johnson PJ; Lo YM
Clin Cancer Res; 2002 Jan; 8(1):29-34. PubMed ID: 11801537
[TBL] [Abstract][Full Text] [Related]
34. [The clinical value of quantitative analysis of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma].
Yuan H; Yang BB; Xu ZF
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Mar; 39(3):162-5. PubMed ID: 15283296
[TBL] [Abstract][Full Text] [Related]
35. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.
Chan JY; Wong ST
Laryngoscope; 2014 Jan; 124(1):126-30. PubMed ID: 23686740
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus infection in precursor lesions of nasopharyngeal carcinoma.
Zhong BL; Zong YS; Lin SX; Zhang M; Liang YJ
Ai Zheng; 2006 Feb; 25(2):136-42. PubMed ID: 16480574
[TBL] [Abstract][Full Text] [Related]
37. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
39. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy.
An X; Wang FH; Ding PR; Deng L; Jiang WQ; Zhang L; Shao JY; Li YH
Cancer; 2011 Aug; 117(16):3750-7. PubMed ID: 21319149
[TBL] [Abstract][Full Text] [Related]
40. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
Gandhi MK; Lambley E; Burrows J; Dua U; Elliott S; Shaw PJ; Prince HM; Wolf M; Clarke K; Underhill C; Mills T; Mollee P; Gill D; Marlton P; Seymour JF; Khanna R
Clin Cancer Res; 2006 Jan; 12(2):460-4. PubMed ID: 16428487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
